纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展

陈自强, 张玮, 李玉平, 王晓宇

文章导航 > 药学实践与服务 > 2016 > 34(2): 103-105

陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

引用本文:

陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

Citation:

CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展

doi: 10.3969/j.issn.1006-0111.2016.02.002

1.
第二军医大学附属长海医院骨科, 上海 200433
2.
同济大学附属上海市肺科医院药剂科, 上海 200433
3.
第二军医大学附属长海医院药学部, 上海 200433

Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma

1.
Department of Orthopaedics, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China
2.
Department of Pharmacy, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China
3.
Department of Pharmacy, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

摘要: 多药耐药是肿瘤化疗中的重要难题,多药耐药的机制复杂,目前尚无有效的治疗策略。纳米载药系统具有靶向性、载药种类多样等优点,近年来成为对抗肿瘤多药耐药的递药载体的重要研究方向。对肿瘤抑制的不同机制进行讨论,并对纳米载药系统逆转骨肉瘤多药耐药的研究进展进行综述。
- 肿瘤 /
- 骨肉瘤 /
- 多药耐药 /
- 纳米载药系统
Abstract: Multidrug resistance(MDR) of tumor cell is the major problem for chemotherapy. However, there is no effective strategy to overcome MDR due to the complicated mechanism. The nano-sized drug delivery system could target to the tumor cell. Moreover, it could delivery different kinds of drugs. Therefore, the nano-sized drug delivery system has become a promising approach to reverse MDR. The nano-sized drug delivery system which is applied to treat the MDR of tumor(osteosarcoma) was summarized and the reverse mechanism was discussed.
- tumor /
- osteosarcoma /
- MDR /
- nano-sized drug delivery system

[1]	Palakurthi S, Yellepeddi VK, Vangara KK. Recent trends in cancer drug resistance reversal strategies using nanoparticles[J]. Expert Opin Drug Deliv, 2012, 9(3):287-301.
[2]	Shapira A, LivneyY D, Broxterman H J, et al. Nanomedicine for targeted cancer therapy:towards the overcoming of drug resistance[J]. Drug Resist Updat, 2011, 14(3):150-163.
[3]	Patil YB, Swaminathan SK, Sadhukha T, et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance[J]. Biomaterials, 2010, 31(2):358-365.
[4]	Song XR, Cai Z, Zheng Y, et al. Reversion of multidrug resistance by coencapsulation of vincristine and verapamil in PLGA nanoparticles[J]. Eur J Pharm Sci, 2009, 37(3-4):300-305.
[5]	Khdair A, Handa H, Mao GZ, et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro[J]. Eur J Pharm Biopharm, 2009, 71(2):214-222.
[6]	Lee ES, Gao ZG, Kim D, et a1. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e)specific TAT exposure and multidrug resistance[J]. J Control Rel, 2008, 129(3):228.
[7]	Chen B, Sun Q, Wang X, et al. Reversal in multidrug resistance by magnetic nanoparticle of Fe₃O₄ loaded with adriamycin and tetrandrine in K562/A02 leukemic cells[J]. Int J Nanomedicine, 2008, 3(2):277-286.
[8]	Chen BA, Cheng J, Shen MF, et al. Magnetic nanoparticle of Fe₃O₄ and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells[J]. Int J Nanomedicine, 2009, 4:65-71.
[9]	Chen BA, Lai BB, Cheng J, et al. Daunorubicin-loaded magnetic nanoparticles of Fe₃O₄ overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo[J]. Int J Nanomed, 2009, 4:201-208.
[10]	Chen AM, Zhang M, Wei DG, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells[J]. Small, 2009, 5(23):2673-2677.
[11]	WangY, Saad M, Pakunlu RI, et al. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor[J]. Clin Cancer Res, 2008, 14(11):3607-3616.
[12]	Devalapally H, Duan ZF, Seiden MV, et al. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles[J]. Clin Cancer Res, 2008,14(10):3193-3203.
[13]	Fan L, Li F, Zhang HT, et al. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance[J]. Biomaterials, 2010, 31(21):5634-5642.
[14]	Susa M, Iyer AK, Ryu K, et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma[J]. BMC Cancer,2009, 9:399.
[15]	Susa M, Iyer AK, Ryu K, et al. Inhibition of ABCB1(MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma[J]. PLoS One, 2010, 5(5):e10764.

[1]	田硕, 厉建中. 转录因子ZNF24在肿瘤中的研究进展 . 药学实践与服务, 2023, 41(12): 710-713, 721. doi: 10.12206/j.issn.2097-2024.202204043
[2]	方宇昕, 李育, 刘宝姝, 董国强. 线性泛素连接酶复合体与去线性泛素化酶在肿瘤中的研究进展 . 药学实践与服务, 2023, 41(9): 534-539. doi: 10.12206/j.issn.2097-2024.202307045
[3]	高习清, 卢光照, 鲁莹, 邹豪. 活性氧自由基响应型脂质体在抗肿瘤研究中的应用进展 . 药学实践与服务, 2023, 41(1): 14-17. doi: 10.12206/j.issn.2097-2024.202105086
[4]	戴佳炜, 施赛健, 宋瑷蔚, 王志斌, 庄春林, 夏春年. 吲哚查尔酮衍生物FC58的抗白血病多药耐药活性研究 . 药学实践与服务, 2021, 39(4): 305-308. doi: 10.12206/j.issn.1006-0111.202012008
[5]	丁佳宁, 马进原, 朱全刚. 长链非编码RNA人母系表达基因3在肿瘤发生中作用的研究进展 . 药学实践与服务, 2019, 37(5): 390-393,421. doi: 10.3969/j.issn.1006-0111.2019.05.002
[6]	施赛健, 张文, 厉廷有, 庄春林. 抗肿瘤多药耐药微管蛋白调节剂的研究进展 . 药学实践与服务, 2017, 35(5): 385-393,397. doi: 10.3969/j.issn.1006-0111.2017.05.001
[7]	康烨, 周密, 阎澜. 真菌多药耐药外排机制的研究进展 . 药学实践与服务, 2016, 34(6): 485-488. doi: 10.3969/j.issn.1006-0111.2016.06.002
[8]	王欢, 马志强, 杨峰. 用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展 . 药学实践与服务, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
[9]	王欢, 佘岚, 王琳召, 马志强, 张欣荣, 杨峰. 氧化介孔碳球纳米粒作为紫杉醇载体的研究 . 药学实践与服务, 2015, 33(2): 114-118. doi: 10.3969/j.issn.1006-0111.2015.02.005
[10]	赵心彬, 倪敏, 陶霞. 他汀类药物多效药理作用及其机制研究进展 . 药学实践与服务, 2013, 31(1): 19-21. doi: 10.3969/j.issn.1006-0111.2013.01.005
[11]	陈婷, 鲁莹. 载抗肿瘤药物纳米靶向给药系统的研究进展 . 药学实践与服务, 2011, 29(3): 176-178,196.
[12]	周忻. 50例肿瘤科住院患者的中药用药情况分析 . 药学实践与服务, 2009, 27(1): 55-57.
[13]	章忱, 程康, 郭炜, 卫洪昌. 麝香保心丸对裸小鼠人结肠癌肝转移模型促血管新生因子及肿瘤生长的影响 . 药学实践与服务, 2007, (5): 295-296,302.
[14]	侯雪梅, 崔黎丽, 李国栋, 李卫华. 抗肿瘤药物靶向制剂研究进展 . 药学实践与服务, 2007, (5): 273-275,280.
[15]	丁力, 丁家崇, 郭葆玉. 抗肿瘤药物新靶点半胱天冬酶-10 . 药学实践与服务, 2006, (2): 76-79.
[16]	庞晓军, 黄军章, 刘国勇, 李香乐. 肿瘤基因治疗研究进展 . 药学实践与服务, 2006, (1): 4-6.
[17]	王彦, 刁亚英, 姜远英. ABC转运蛋白与肿瘤多药耐药 . 药学实践与服务, 2003, (1): 28-31.
[18]	王晶, 潘勇华, 王旭明, 刘建飞. 光敏剂及其临床应用进展 . 药学实践与服务, 2002, (2): 67-70.
[19]	范开华, 刘子文, 夏俊. 血卟啉二乙二醇对消化道肿瘤的光动力疗效观察 . 药学实践与服务, 2001, (2): 76-76.
[20]	范开华, 温定量, 周明惠, 夏俊. 2,7,12,18-四甲基-3,8-二(1-甲氧乙基)-13,17-二(3-乙胺基丙基)卟啉衍生物的合成及其光敏活性 . 药学实践与服务, 1999, (6): 344-346.

WeChat

点击查看大图

计量

文章访问数: 2462
HTML全文浏览量: 244
PDF下载量: 14
被引次数: 0

纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展

doi: 10.3969/j.issn.1006-0111.2016.02.002

1. 第二军医大学附属长海医院骨科, 上海 200433

2. 同济大学附属上海市肺科医院药剂科, 上海 200433

3. 第二军医大学附属长海医院药学部, 上海 200433

收稿日期: 2014-12-21
修回日期: 2015-05-06

关键词:

纳米载药系统

摘要: 多药耐药是肿瘤化疗中的重要难题,多药耐药的机制复杂,目前尚无有效的治疗策略。纳米载药系统具有靶向性、载药种类多样等优点,近年来成为对抗肿瘤多药耐药的递药载体的重要研究方向。对肿瘤抑制的不同机制进行讨论,并对纳米载药系统逆转骨肉瘤多药耐药的研究进展进行综述。

English Abstract

陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

引用本文:

陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

Citation:

CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

全文HTML

参考文献 (15)

/

下载: 全尺寸图片幻灯片

分享

用微信扫码二维码

分享至好友和朋友圈

返回

版权所有：《药学实践与服务》编辑委员会

主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号沪ICP备05003363号-1

本系统由北京仁和汇智信息技术有限公司开发